Listing of Claims:

1. Use of a composition in the manufacture of a medicament for the treatment of ~~A method of treating~~ a solid tumor in a subject,

the medicament comprising ~~administering to the subject an effective amount of~~ a compound having the formula:



;

or a pharmaceutically acceptable salt thereof; and

a~~n effective amount of~~ second agent selected from a topoisomerase inhibitor, a DNA alkylating agent, and an androgen receptor signaling inhibitor.

2. Use of a compound in the manufacture of a medicament for administration with a second agent to treat a solid tumor in a subject,

the compound having the formula:



;

or a pharmaceutically acceptable salt thereof; and

wherein the second agent is selected from a topoisomerase inhibitor, a DNA alkylating agent, and an androgen receptor signaling inhibitor.

3. The use of Claim 2, wherein the medicament is formulated for concurrent administration with the second agent.

4. The use of Claim 2, wherein the medicament is formulated for sequential administration with the second agent.

5~~2~~. The ~~method~~ use of any one of Claims 1 to 4, wherein the second agent is an androgen receptor signaling inhibitor.

6~~3~~. The ~~method~~ use of any one of Claims 1 to 5~~or 2~~, wherein the second agent is an androgen receptor signaling inhibitor selected from bicalutamide, enzalutamide, apalutamide, flutamide, nilutamide, darolutamide, and abiraterone acetate.

7~~4~~. The use~~method~~ of any one of Claims 1 to 6~~3~~, wherein the second agent is enzalutamide.

8~~5~~. The use~~method~~ of any one of Claims 1 to 4, wherein the second agent is a DNA alkylating agent.

9~~6~~. The use~~method~~ of any one of Claims 1 to 4 or 8~~5~~, wherein the DNA alkylating agent is selected from busulfan, cyclophosphamide, bendmustine, carboplatin, chlorambucil, cyclophosphamide, cisplatin, temozolomide, melphalan, carmustine, lomustine, dacarbazine, oxaliplatin, ifosamide, thiotepa, trabectedin, altretamine, mechlorethamine, procarbazine, and streptozocin.

10~~7~~. The use~~method~~ of any one of Claims 1 to 4 or 8~~5~~, wherein the DNA alkylating agent is cisplatin.

11~~8~~. The use~~method~~ of any one of Claims 1 to 4, wherein the second agent is a topoisomerase inhibitor.

12~~9~~. The use~~method~~ of any one of Claims 1 to 4 or 11~~8~~, wherein the topoisomerase inhibitor is a topoisomerase I inhibitor.

13~~10~~. The use~~method~~ of any one of Claims 1 to 4 or 11~~8~~, wherein the topoisomerase inhibitor is selected from irinotecan, topotecan, camptothecin, lamellarin, etoposide, teniposide, doxorubicin, daunorubicin, mitoxantrone, amsacrine, ellipticines,

aurintricarboxylic acid, HU-331, epirubicin, valrubicin, idarubicin, pixantrone, teniposide, belotecan, gimatecan, indotecan, indimitecan.

1411. The usemethod of any one of Claims 1 to 4, 118, and 129, wherein the topoisomerase inhibitor is irinotecan.

1512. The usemethod of any one of Claims 1 to 1411, wherein the solid tumor is selected from prostate cancer, small cell lung cancer (SCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, and serous ovarian cancer.

1613. The usemethod of any one of Claims 1 to 1512, wherein the solid tumor is selected from small cell lung cancer (SCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, and serous ovarian cancer.

1714. The usemethod of any one of Claims 1 to 1512, wherein the solid tumor is prostate cancer.

1815. The usemethod of any one of Claims 1 to 1714, wherein the solid tumor is characterized as an advanced tumor.

1916. The usemethod of any one of Claims 1 to 1815, wherein the solid tumor is characterized as a relapsed solid tumor.

~~17. The method of any one of Claims 1 to 16, wherein the compound is administered concurrently with the second agent.~~

~~18~~20. The usemethod of any one of Claims 1 to 19~~17~~, wherein the compound is of the formula



;

or a pharmaceutically acceptable salt thereof.

~~19~~21. Use of ~~A method of treating an advanced relapsed solid tumor using~~ 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide; or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of an advanced relapsed solid tumor.

~~20~~22. The use~~method~~ of Claim 21~~19~~, wherein the advanced relapsed solid tumor is advanced relapsed urothelial carcinoma, advanced relapsed ovarian clear cell carcinoma, or advanced relapsed endometrial carcinoma.

~~21~~23. The ~~method~~ use of Claim 21~~19~~ or 22~~20~~, wherein the 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is (2R)-7-chloro-2-(trans-4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide.